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Abstract
Neuropathic pain is a debilitating clinical condition with few efficacious treatments, warranting development of
novel therapeutics. We hypothesized that dysregulated translation regulation pathways may underlie neuropathic
pain. Peripheral nerve injury induced reorganization of translation machinery in the peripheral nervous system of
rats and mice, including enhanced mTOR and ERK activity, increased phosphorylation of mTOR and ERK
downstream targets, augmented eIF4F complex formation and enhanced nascent protein synthesis. The AMP
activated protein kinase (AMPK) activators, metformin and A769662, inhibited translation regulation signaling
pathways, eIF4F complex formation, nascent protein synthesis in injured nerves and sodium channel-dependent
excitability of sensory neurons resulting in a resolution of neuropathic allodynia. Therefore, injury-induced
dysregulation of translation control underlies pathology leading to neuropathic pain and reveals AMPK as a novel
therapeutic target for the potential treatment of neuropathic pain.
Background
Neuropathic pain is a debilitating condition wherein a
large cohort of patients fail to achieve even partial pain
relief [1]. Hence, novel treatment approaches targeting
molecular mechanisms of pathology induced by periph-
eral nerve injury (PNI) are needed. PNI leads to changes
in sensory neuron phenotype and function resulting in
hyperexcitability and ectopic activity in these neurons
driving neuropathic pain [2]. The important role of
translation regulation in learning and memory has eluci-
dated translation control as a critical factor for neuronal
plasticity [3]. Multiple lines of evidence suggest that
translation regulation at the level of the primary afferent
neuron is crucial for the establishment and maintenance
of enhanced pain states [4-9]. Several recent reports
have suggested an important role for the mammalian
target of rapamycin complex 1 (mTORC1) pathway in
neuropathic pain [4,6]; however, mechanistic links
between mTORC1 and pathology induced by PNI are
still lacking. Moreover, treatment strategies that target
translation control have not been clearly identified as
potential treatments for neuropathic pain.
Translation control is orchestrated by upstream
kinases that signal to the translation machinery [10].
These kinases can be targeted individually by selective
inhibitors or they can be negatively modulated by endo-
genous signaling factors that act on these pathways [11].
A crucial kinase for negative regulation of translation is
the ubiquitous, energy-sensing kinase AMP-activated
protein kinase (AMPK). Activation of AMPK by deple-
tion of cellular nutrients or through pharmacological
intervention results in a dampening of signaling to the
translation machinery [11] but the potential effects of
AMPK activation on neuronal excitability, an important
component of neuropathic pain conditions [2], is not
known. AMPK can be targeted pharmacologically via a
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A769662) and by the widely clinically available and rela-
tively safe drug metformin.
Herein we have tested the hypothesis that AMPK may
represent a novel and efficacious opportunity for the
treatment of chronic neuropathic pain. We find that
PNI is linked to reorganization of translation machinery
in injured nerves and demonstrate that pharmacological
activation of AMPK leads to normalization of aberrant
gene expression at the level of translation, decreased
sensory neuron excitability and the resolution of neuro-
pathic allodynia in preclinical models. Importantly, these
effects are achieved by metformin suggesting an imme-
diately available novel avenue for the potential treatment
of neuropathic pain in humans. Hence, AMPK repre-
sents a novel therapeutic target for the treatment of
neuropathic pain disorders.
Results
PNI induces a major reorganization of translational
machinery in the peripheral nervous system
We utilized the rat spinal nerve ligation (SNL) and
mouse spared nerve injury (SNI) models to assess bio-
chemical changes in translation machinery occurring
after PNI in the dorsal root ganglion (DRG) and sciatic
nerve. SNL induced a significant increase in translation
regulation signaling pathway components as well as
translation machinery in the uninjured and injured DRG
and in the sciatic nerve (Figure 1A). In the uninjured
DRG (L4, Figure 1A) these changes included increased
phosphorylation of mTOR, eukaryotic initiation factor
(eIF) 4E binding protein (4EBP) and increased total
4EBP. Phosphorylation of eIF2a is negatively correlated
with translation [12] and, consistent with enhanced
translation in the L4 DRG, we observed decreased p-
eIF2a (Figure 1A). Proteins associated with RNA pro-
cessing and binding (e.g. Moloney leukemia virus 10
(Mov10) [13]) were also increased (see Table 1 for
quantification). Likewise, in the injured DRGs (L5/6) p-
mTOR and p-4EPB were increased as well as total
mTOR. Increases in total Mov10 and fragile × mental
retardation protein (FMRP) were also observed (Figure
1A, see Table 2 for quantification).
SNL induces a degeneration of axons from the L5 and
L6 DRGs resulting in pathology to uninjured sciatic
axons originating from L4 DRG [2] that comingle in the
nerve. In the sciatic nerve, PNI led to enhanced mTOR
and extracellular signalregulated kinase (ERK) pathway
activity reflected by increased p-4EBP, p-ribosomal S6
protein (rS6p) and p-eIF4E, respectively. Upstream acti-
vation of mTOR in this setting is likely linked to
enhanced AKT activity as increased p-AKT and p-
mTOR at S2448 was observed [14]. We have recently
shown that nerve growth factor (NGF) and interleukin 6
(IL-6) signal to the translational machinery in dorsal
root ganglion (DRG) and trigeminal ganglion (TG) neu-
ronal axons via mTOR and ERK, respectively [7]. We
found that NGF (ipsilateral 1532 ± 185.6 pg/ml vs. con-
tralateral 924.5 ± 55.7 pg/ml, p = 0.011) and IL-6 (ipsi-
lateral 1282 ± 100.8 pg/ml vs. contralateral 988.6 ± 35.2
pg/ml; p = 0.021) were increased by PNI in the sciatic
nerve suggesting that NGF and IL-6 may contribute to
local mTOR and ERK activation following injury. We
further noted increases in translational machinery (total
eIF4E, eIF4A, eIF2a) and RNA processing and binding
proteins (FMRP, Mov10 and rck/p54; Figure 1A, see
Table 3 for quantification). Hence, these results demon-
strate a fundamental reorganization of translation signal-
ing pathways and machinery in the sciatic nerve induced
by PNI.
To verify that these findings are generalized to other
models of PNI in other species, we utilized the mouse
SNI model to confirm reorganization of biochemical
components mediating translation regulation. In the
injured sciatic nerve of the mouse SNI model we
observed an upregulation of total 4EBP, eIF4E, eIF4A,
Mov10 and rck/p54 and increased ERK activity (Figure
1B, see Table 4 for quantification). To demonstrate loca-
lization of enhanced mTOR signaling to DRG axons we
used immunohistochemistry (IHC) for p-mTOR. Unin-
jured sciatic nerves from rats did not exhibit detectable
levels of p-mTOR on serine 2448 (Figure 1C). However,
following PNI robust p-mTOR IHC co-localized with
markers of DRG neuron axons (peripherin + N52, Fig-
ure 1C). Collectively, these findings support the conclu-
sion that PNI induces a fundamental reorganization of
translation regulation signaling in the injured PNS and
IHC findings with p-mTOR suggest that these changes
occur in sensory neuron axons.
PNI enhances eIF4F complex formation and causes an
increase in nascent protein synthesis in the sciatic nerve
To directly demonstrate stabilization of the eIF4F com-
plex on the 5’-mRNA-cap we incubated proteins
extracted from sciatic nerves ipsilateral and contralateral
to SNL with sepharose beads conjugated to 7-methyl-
GTP. Ipsilateral to the injury we observed 1200%
increase in eIF4A association with the 7-methyl-GTP
conjugated beads (Figure 2A and 2C). Conversely, only
a modest increase in 4EBP was detected associated with
7-methyl-GTP (Figure 2A and 2B) despite a robust
increase in total 4EBP induced by PNI (Figure 1A and
1B). The ratio of eIF4A to 4EBP (750% increase; Figure
2D) associated with 7-methyl-GTP strongly suggests a
robust increase in cap-dependent translation in the scia-
tic nerve induced by PNI. To directly ascertain altered
nascent protein synthesis following PNI we incubated
excised sciatic nerves ipsilateral and contralateral to
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logue L-azidohomoalanine (AHA) [15,16]. AHA incor-
poration into nascently synthesized proteins was
biotinylated using click-chemistry and detected by Wes-
tern blotting. With 2 hr incubation, injured nerves
incorporated 50% more AHA than either contralateral
uninjured nerves or sciatic nerves taken from sham rats
(Figure 2E and 2F). Taken together, these findings
directly demonstrate that PNI-induced reorganization of
translation regulation in the sciatic nerve results in
enhanced eIF4F complex formation and increased pro-
tein synthesis.
AMPK activators reverse PNI induced allodynia
We hypothesized that activation of AMPK signaling may
represent a novel mechanism for treatment of
Figure 1 PNI induces a fundamental reorganization of translation signaling and machinery in the injured PNS. A) PNI in rats causes
upregulation of translation machinery and signaling pathways associated with protein translation. These changes are observed in the injured
sciatic nerve and in both injured (L5 and L6) and uninjured (L4) DRGs. B) PNI in mice increases proteins that enhance translation and associated
signaling pathways. In both panels, up arrows indicate an increase while down arrows indicate a decrease; numbers indicate fold change in
ipilateral vs. contralateral (right) and phospho-protein vs. total protein (left). C) Immunohistochemical colocalization of p-mTOR with sensory
neuronal markers (peripherin + N52) show that activated mTOR localizes to axons of injured sciatic nerve from rats with SNL.
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pathway, is associated with decreased ERK activity [11]
and inhibits insulin receptor substrate (IRS)-mediated
feedback signaling [17]. Metformin stimulates the
AMPK pathway through multiple mechanisms [18,19].
Mice treated with metformin (200 mg/kg/day [20] for 7
days) starting 2 (Figure 3A) or 7 (Figure 3B) weeks
post-SNI displayed a complete reversal of tactile allody-
nia. No changes in threshold were observed in sham
mice (Figure 3A and 3B). Likewise, treatment with
Table 1 Quantification of western blots on ipsilateral vs
contralateral L4 (uninjured) DRGs from SNL rats 17 days
post-surgery.
RAT SNL
Uninjured L4 DRG vs. Contralateral
Contra Contra Ipsi Ipsi
Protein/Standardization Mean % SEM Mean % SEM P-value
p-mTOR/mTOR 100 17.9 402.8 63.6 0.001
p-mTOR/beta III tubulin 100 19.0 425.7 92.0 0.012
mTOR/beta III tubulin 100 12.1 86.0 34.4 NS
p-4EBP/4EBP 100 11.6 100.1 9.3 NS
p-4EBP/beta III tubulin 100 15.8 190.3 22.2 0.003
4EBP/beta III tubulin 100 17.8 182.6 14.8 0.002
p-ERK/ERK 100 11.0 121.0 17.1 NS
p-ERK/beta III tubulin 100 19.8 111.3 13.2 NS
ERK/beta III tubulin 100 12.3 97.2 4.0 NS
p-eIF4alpha/eIF4alpha 100 13.5 60.1 8.0 0.026
p-eIF2alpha/beta III tubulin 100 19.7 61.8 7.2 NS
eIF2alpha/beta III tubulin 100 13.6 106.9 6.3 NS
mov10/beta III tubulin 100 20.8 220.9 37.0 0.008
rck/beta III tubulin 100 12.5 123.5 14.1 NS
eIF4A/beta III tubulin 100 15.3 102.5 14.7 NS
fbxw7/beta III tubulin 100 45.1 102.3 30.5 NS
p-AKT/total AKT 100 10.9 112.8 14.7 NS
p-AKT/beta III tubulin 100 6.0 107.8 12.2 NS
AKT/beta III tubulin 100 10.8 92.5 3.9 NS
p-mTOR/GAPDH 100 14.1 387.2 72.4 0.006
p-4EBP/GAPDH 100 13.3 162.6 12.0 0.002
4EBP/GAPDH 100 11.8 163.1 9.6 0.000
mov10/GAPDH 100 19.4 195.6 34.6 0.025
Table 2 Quantification of western blots on ipsilateral vs.
contralateral L5 and L6 (injured) DRGs from SNL rats 17
days post-surgery.
RAT SNL
Injured L5/L6 DRG vs. Contralateral
Contra Contra Ipsi Ipsi
Protein/Standardization Mean % SEM Mean % SEM P-value
p-mTOR/mTOR 100.0 22.2 71.6 16.2 NS
p-mTOR/beta III tubulin 100.0 27.5 321.0 59.1 0.003
mTOR/beta III tubulin 100.0 23.6 579.4 178.3 0.016
p-4EBP/4EBP 100.0 12.7 98.4 7.3 NS
p-4EBP/beta III tubulin 100.0 33.1 222.1 46.2 0.049
4EBP/beta III tubulin 100.0 42.2 179.8 18.7 NS
FMRP/beta III tubulin 100.0 29.3 199.0 36.6 0.047
mov10/beta III tubulin 100.0 36.4 875.0 304.2 0.035
Table 3 Quantification of western blots on ipsilateral vs.
contralateral sciatic nerves from SNL rats 17 days post-
surgery.
RAT SNL
Sciatic Nerve Ipsilateral vs. Contralateral
Contra Contra Ipsi Ipsi
Protein/Standardization Mean % SEM Mean % SEM P-value
p-mTOR/mTOR 100 27.6 581.8 112.0 0.002
p-4EBP/4EBP 100 8.9 117.0 13.6 NS
p-4EBP/4EBP 100 12.6 408.0 104.2 0.008
p-rS6/beta III-tubulin 100 22.6 1005.5 300.0 0.007
p-AKT/AKT 100 17.3 101.6 22.0 NS
p-AKT/beta III-tubulin 100 14.4 276.4 67.5 0.034
AKT/beta III-tubulin 100 11.2 261.6 36.9 0.003
p-ERK/ERK 100 8.8 510.3 153.4 0.023
p-eIF4E/eIF4E 100 14.8 164.0 17.6 0.024
p-eIF4E/beta III-tubulin 100 25.1 700.8 168.5 0.008
eIF4E/beta III-tubulin 100 16.8 415.4 62.7 0.001
eIF4A/beta III-tubulin 100 14.6 241.0 31.0 0.001
p-eIF2alpha/eIF2alpha 100 8.9 110.7 21.4 NS
p-eIF2alpha/beta III-tubulin 100 15.3 506.4 163.4 0.024
eIF2alpha/beta III-tubulin 100 19.5 575.7 107.9 0.001
FMRP/beta III-tubulin 100 14.2 257.8 59.0 0.024
mov10/beta III-tubulin 100 28.5 636.3 161.2 0.008
rck/beta III-tubulin 100 22.9 483.4 141.4 0.015
fbxw7/beta III-tubulin 100 37.7 305.7 72.9 0.028
p-4EBP/GAPDH 100 25.4 224.6 18.6 0.004
4EBP/GAPDH 100 26.1 257.4 32.5 0.006
p-eIF4E/GAPDH 100 15.9 458.0 54.4 0.000
eIF4E/GAPDH 100 10.6 270.2 12.4 0.000
p-eIF2alpha/GAPDH 100 10.3 297.4 74.9 0.018
eIF2alpha/GAPDH 100 4.7 244.3 15.7 0.000
rck/GAPDH 100 20.5 280.0 62.2 0.013
p-AKT/GAPDH 100 8.4 182.8 26.1 0.017
AKT/GAPDH 100 14.1 177.2 18.6 0.011
eIF4A/GAPDH 100 9.3 249.6 33.0 0.001
fbxw7/GAPDH 100 25.4 420.6 134.1 0.037
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teric modulator of AMPK [21], led to a full reversal of
tactile allodynia with no effect in shams (Figure 3C).
Metformin (200 mg/kg/day for 7 days) also alleviated
SNL-induced neuropathic allodynia without influencing
thresholds in sham rats (Figure 3D). No adverse motor
effects were observed in sham or PNI animals. These
results establish AMPK activators as a potentially effica-
cious class of drugs for the treatment of PNI-induced
neuropathic pain.
AMPK activators reverse PNI-induced biochemical
changes
We asked if AMPK activators inhibit signaling pathways
associated with translation regulation in sensory neurons
in the presence of nerve growth factor (NGF). We used
mouse TG neurons for these studies because we have
previously shown that NGF signaling to ERK and
mTOR in vitro is identical in TG and DRG neurons
from this species [7]. Utilizing TG neurons greatly
reduces the number of animals required for these stu-
dies. NGF promotes mTOR and ERK signaling pathways
in these neurons [7], contributes to neuropathic pain in
preclinical models [22] and is associated with neuro-
pathic pain in humans [23]. Mouse TG neurons were
treated with metformin (Figure 4A), A769662 (Figure
4B) or AICAR (Figure 4C) for 1 hour. A769662 and
AICAR activated AMPK and suppressed activity in the
mTOR and ERK pathways whereas metformin activated
AMPK and selectively inhibited the mTOR pathway but
did not lead to feedback signaling through IRS (e.g. no
increase in ERK or AKT phosphorylation [24]). More-
over, A769662 and metformin inhibited eIF4F complex
formation (Figure 5A and 5B) in primary cultures of TG
neurons treated with NGF. To determine if metformin
inhibited dysregulated translation in vivo,w ee x c i s e d
sciatic nerves from SNL rats treated with vehicle or
metformin (200 mg/kg/day for 7 days). A 50% increase
in nascently synthesized proteins was observed in the
sciatic nerve of SNL rats treated with vehicle, whereas
Table 4 Quantification of western blots on ipsilateral vs.
contralateral sciatic nerves from SNI mice 17 days post-
surgery.
MOUSE SNI
Sciatic Nerve Ipsilateral vs. Contralateral
Contra Contra Ipsi Ipsi
Protein/Standardization Mean % SEM Mean % SEM P-value
p-mTOR/mTOR 100 7.6 128.0 19.6 NS
p-mTOR/beta III tubulin 100 13.4 211.4 68.9 NS
mTOR/beta III tubulin 100 14.0 155.7 42.1 NS
p-4EBP/4EBP 100 5.8 94.0 5.7 NS
p-4EBP/beta III tubulin 100 15.0 150.6 17.6 0.049
4EBP/beta III tubulin 100 14.6 169.6 23.0 0.025
p-ERK/ERK 100 13.6 511.9 187.6 0.049
p-ERK/beta III tubulin 100 13.3 500.4 109.5 0.003
ERK/beta III tubulin 100 8.3 111.1 8.8 NS
p-eIF4E/eIF4E 100 25.5 104.9 13.1 NS
p-eIF4E/beta III tubulin 100 22.7 301.0 41.3 0.001
eIF4E/beta III tubulin 100 13.2 283.0 42.5 0.001
eIF4A/beta III tubulin 100 16.8 185.9 28.0 0.022
mov 10/beta III tubulin 100 31.6 256.9 41.0 0.011
rck/beta III tubulin 100 26.3 482.7 155.0 0.032
fbxw7/beta III tubulin 100 35.7 133.4 42.2 NS
Figure 2 PNI enhances cap-dependent protein translation in the injured sciatic nerve. A) Western blot of eIF4A, 4EBP and eIF4E from
sciatic nerve co-precipitated using 7-methyl-GTP conjugated beads. B) PNI induces only 50% increase in 4EBP (negative regulator of translation)
association with cap-binding protein eIF4E, C) while injury induces a 1200% increase in the association of eIF4A (a component of eIF4F complex)
with eIF4E. D) PNI induces a 750% increase in the ratio of eIF4A to 4EBP associated with eIF4E bound to 7-methyl-GTP conjugated beads. PNI
increases nascent protein synthesis in injured sciatic nerve. E) Western blot of AHA incorporated into nascently synthesized proteins. F) PNI
induces a 50% increase in the incorporation of AHA into nascently synthesized proteins. All samples taken 17 days post SNL from rats with n = 6
per condition. *p < 0.05.
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tein levels to those observed in uninjured sciatic nerves
(Figure 5C). Hence, AMPK activators suppress transla-
tion regulation pathways in sensory neurons and inhibit
nascent protein synthesis in the sciatic nerve associated
with PNI.
AMPK activators block hyperexcitability in sensory
neurons
Based on the biochemical findings above, we hypothe-
sized that AMPK activators might attenuate ramp cur-
rent-evoked sensory neuron excitability. Small diameter
(20-30 pF), mouse TG neurons cultured in the presence
of NGF displayed increased excitability when stimulated
with depolarizing ramp current injections (Figure 6A, B
and 6C). Treatment with metformin restored these para-
meters to levels observed in vehicle-treated cultures
(Figure 6A, B and 6C). Treatment with A769662 dose-
dependently prolonged latency to first action potential
(Figure 6C) and potently reduced the number of action
potentials in response to ramp currents (Figure 6A).
This effect persisted for at least 1hr after washout (Fig-
ure 6) demonstrating that the observed effects are not
due to direct channel blockade. AMPK activators did
not significantly influence resting membrane potential
(vehicle = -60.52 ± 0.74; NGF + vehicle = -60.61 ± 0.70;
NGF + metformin = -61.27 ± 1.22; NGF + A769662 (50
μM) = -58.3 ± 1.63; NGF + A769662 (200 μM) = -56.13
± 2.37) after one hr exposure. As noted in biochemical
experiments, A769662 suppressed ERK activation in
sensory neurons (Figure 4B) whereas metformin only
influenced the mTOR pathway (Figure 4A). This discre-
pancy in signaling, which likely reflects differential phar-
macological upstream mechanisms of these compounds
[19,21], may provide insight into the enhanced efficacy
of A769662 in reducing sensory neuron excitability in
response to ramp currents. Thus, AMPK activators not
only suppress translation regulation signaling and eIF4F
complex formation but also decrease the excitability of
sensory neurons.
Figure 3 AMPK activators reduce PNI-induced neuropathic allodynia. Daily intraperitoneal injections of metformin in mice starting 2 (A) or
7 (B) weeks post PNI leads to a reversal of mechanical allodynia. C) A769662 daily treatment also reversed PNI-induced allodynia when started 2
weeks post PNI. D) Treatment of SNL rats (2 weeks post surgery) with metformin also significantly reduces neuropathic allodynia. N = 6 per
group. **p < 0.01 and ***p < 0.001.
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The present findings provide several novel insights into
the pathology and potential treatment of neuropathic
pain. We have demonstrated that PNI induces a major
reorganization of translation regulation signaling, trans-
lation machinery and RNA-binding proteins in the
injured PNS. These changes are directly linked to
increased eIF4F complex formation and augmented nas-
cent protein synthesis. We have identified AMPK activa-
tion as a novel avenue for the potential treatment of
neuropathic pain in humans. Metformin and A769662
both alleviated neuropathic allodynia, inhibited transla-
tion regulation pathways associated with PNI and
decreased sensory neuronal excitability. No clinical trials
have assessed the efficacy of metformin for neuropathic
pain. These studies provide a compelling preclinical
rationale for the clinical assessment of metformin for
neuropathic pain in humans and for the future develop-
ment of more efficacious AMPK activators for the treat-
ment of chronic pain disorders.
Figure 4 Treatment with AMPK activators suppresses translation regulation signaling. A) Treatment of mouse sensory neurons cultured in
the presence of NGF (50 ng/ml) with metformin (2 and 20 mM) for 1 hour induces a dose-dependent increase in the phosphorylation of AMPK.
Metformin treatment abrogates the phosphorylation of mTOR, 4EBP and rS6 in a dose-dependent manner. Metformin does not suppress the
ERK-eIF4E pathway. B) AMPK allosteric activator A769662 suppresses translation regulation signaling. Treatment of mouse sensory neurons with
A769662 (50 and 500 μM) results in a dose dependent suppression of phosphorylation of ERK, eIF4E, mTOR, 4EBP, AKT and rS6. C) Treatment of
mouse sensory neurons with AICAR (0.5 and 2 mM) for 1 hour results in a dose dependent activation of AMPK. Moreover, AICAR dose-
dependently suppresses the phosphorylation of ERK, eIF4E, AKT, TSC2, 4EBP and rS6. N = 6 per group. *p < 0.05, **p < 0.01 and ***p < 0.001.
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neurons contributes to development of the peripheral
and central nervous systems [25], is involved in axonal
regeneration following injury [26,27] and contributes to
pain plasticity [7,8]. Likewise, the repertoire of mRNAs
localized to the axonal compartment is developmentally
regulated and shows plasticity upon injury [26-30].
Interestingly, a recent non-biased approach to mRNA
profiling of the axonal compartment of DRG neurons
revealed a developmental shift toward localization of
mRNAs involved in immune regulation and nociception
in the adult DRG axon [28]. In support of this mRNA
profile, we have recently demonstrated that NGF and/or
IL-6-induced allodynia is dependent on local, axonal
translation from existing pools of axonally localized
mRNAs [7]. The present findings enhance our under-
standing of plasticity of translation control after PNI.
While changes in mRNA localization have been
observed after pre-conditioning peripheral nerve lesions
[26], we found that PNI induces profound changes in
activity of kinases associated with translation control (e.
g. mTOR and ERK), phosphorylation of their down-
stream targets and in overall levels of proteins involved
in RNA processing and transport (e.g. Mov10, FMRP
and rck/p54). This reorganization results in increased
eIF4F complex formation and nascent protein synthesis
in the injured sciatic nerve. Moreover, these changes are
directly correlated to normalization of neuropathic allo-
dynia as metformin reversed changes in protein synth-
esis in injured sciatic nerves and resolved PNI-induced
allodynia.
Protein synthesis is an energy intensive process and,
for this reason, an intricate system to control energy
consumption has evolved in the form of the ubiquitous
kinase, AMPK [11]. Activated AMPK blocks protein
synthesis by inhibiting components of the mTOR and
ERK signaling pathways [11]. Concurrent inhibition of
multiple signaling pathways inherently prevents signal-
ing crosstalk, which is commonly observed with the
i n h i b i t i o no fas i n g l ek i n a s ei n v o l v e di nt h e s es i g n a l i n g
cascades (e.g. inhibition of mTORC1 with rapamycin
[24]). Receptor tyrosine kinases are associated with IRS,
which mediates activation of the mTOR and ERK path-
ways. Inhibition of mTORC1 with rapamycin removes
negative feedback onto IRS, meditated by phosphoryla-
tion of IRS (S1101) by rS6K [31]. Thus, inhibiting
mTORC1 and, in turn, rS6K, with rapamycin releases
disinhibition of IRS signaling resulting in activation of
ERK and mTORC2/AKT pathways [11]. ERK activation
in the PNS is a well known mechanism for increasing
the excitability of nociceptors [32]. For these reasons we
focused on AMPK as a therapeutic target for
Figure 5 AMPK activators suppress translation in sensory
neurons and the injured PNS. Treatment of mouse sensory
neurons cultured in the presence of NGF (50 ng/ml) with A)
Metformin (2 and 20 mM) or B) A769662 (50 and 500 μM) results in
decreased binding of eIF4G and increased 4EBP binding to the
m7GTP-cojugated sepharose beads in a dose-dependent manner
consistent with a decrease in eIF4F complex formation. C)
Metformin treatment of rats with SNL restores nascent protein
synthesis in injured nerves to levels observed in uninjured nerves. N
= 6 per group. *p < 0.05, ** p < 0.01.
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phosphorylation on Serine 794 [17]. Activation of
AMPK with distinct pharmacological tools failed to pro-
mote ERK or AKT activation and, in the case of
A769662 and AICAR, led to inhibition of these kinases.
These findings highlight advantages of targeting AMPK
for the treatment of neuropathic pain.
We have also demonstrated that activation of AMPK
in mouse sensory neurons leads to decreased excitabil-
ity. We used ramp current-evoked spiking to assess the
influence of AMPK activation on sensory neuron excit-
ability. Our findings are consistent with a potential
modulation of the voltage-gated sodium channel Nav1.7
by AMPK activators. Human genetic studies clearly
demonstrate an important role for Nav1.7 in inherited
pain conditions and a growing body of evidence suggests
an important role for Nav1.7 in acquired chronic pain
states [33]. In humans, Nav1.7 expression is increased in
painful neuromas [34] and dental pulp [35,36].
Moreover, inhibition of Nav1.7 decreases sensory neu-
ron excitability [37,38]. Genetic deletion of Nav1.7 in
mice leads to marked decreases in acute and inflamma-
tory pain [39]. Finally, pharmacological inhibition of
Nav1.7 with several distinct classes of inhibitors leads to
a reduction in allodynia in preclinical neuropathic pain
models [40-43]. Hence, human clinical findings and
pharmacological inhibition of Nav1.7 creates a compel-
ling rationale for targeting Nav1.7 in neuropathic pain
disorders. The present findings indicate that the AMPK
signaling axis regulates sensory neuronal activity by
decreasing action potential firing induced by ramp cur-
rent injection and increasing the latency to the first
action potential, both of which are consistent with mod-
ulation of Nav1.7 [44]. We hypothesize that this AMPK-
mediated modulation of sensory neuron excitability may
be linked to inhibition of ERK because ERK phosphory-
lates Nav1.7 altering channel gating properties toward a
hyperexcitable state and leads to decreased neuronal
Figure 6 AMPK activators suppress hyperexcitability of sensory neurons. A) Patch clamp analysis of mouse primary sensory neurons
cultured in the presence of NGF (50 ng/ml, n = 13) demonstrate an increase in the B) number of ramp currentevoked action potentials vs.
vehicle (n = 14) and C) reduced latency to first action potential in response to ramp currents. Metformin (1 hr, n = 14) and A769662 (1 hr, n
=12) reverse these parameters. A769662 effect persists after washout (n = 8). Colored stars denote significant effects compared to the NGF +
Vehicle group. *p < 0.05, **p < 0.01 and ***p < 0.001.
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Page 9 of 14hyperexcitability [44]. While further work will be needed
to directly test the effect of AMPK activators on ERK-
mediated Nav1.7 phosphorylation and Nav1.7 current
kinetics, the present findings demonstrate a role for
AMPK modulation in sensory neuronal excitability.
The results presented here are consistent with a per-
ipheral action for AMPK activators in the alleviation of
SNI- and SNL-induced allodynia; however, we cannot
exclude a potential central mechanism of action. Several
recent studies have demonstrated an important role for
dorsal horn mTOR in preclinical pain models [9,45-49]
and AMPK activators influence the mTOR pathway in
central neurons [50,51]. Moreover, metformin crosses
the blood brain barrier [52]. We favor a peripheral
mechanism of action for several reasons. AMPK activa-
tors had a clear effect on mTOR and, in some cases,
ERK signaling, in cultured sensory neurons. These com-
pounds also negatively influenced the excitability of
these neurons, consistent with the alleviation of neuro-
pathic pain. Moreover, in vivo treatment led to a rever-
sal of PNI-induced enhanced nascent protein synthesis,
consistent with a direct action of AMPK activators on
the injured PNS. Finally, inhibition of translation regula-
tion signaling (e.g. with mTORC1 inhibitors) in the
CNS is thought to play a critical role in the initiation
but not maintenance of plasticity [53]. To this end, we
have recently shown that mTOR inhibiton in the dorsal
horn is incapable of reversing an established preclinical
pain state [47] and, in the setting of neuropathic pain,
other investigators have concluded that even centrally
applied mTOR inhibitors act via inhibition of DRG neu-
ron excitability [4]. Nevertheless, we cannot rule out a
potential CNS site of action for AMPK activators and,
d u et oak e yr o l eo ft r a n s l a t i on regulation in learning
and memory [3] we also cannot rule out a possible
effect of AMPK activators on these processes. Additional
pharmacokinetic/pharmacodynamic studies will be
required to resolve this question with certainty.
The present findings have important implications for
AMPK-based drug discovery for the treatment of pain.
Metformin activates AMPK via LKB1 stimulation [19]
and inhibition of AMP deaminase [18]. AICAR results
in 5-aminoimidazole-4-carboxamide ribonucleoside
accumulation in cells mimicking AMP binding to
AMPK [54]. On the other hand, A769662 is a direct,
positive allosteric modulator of AMPK [21] which
requires the b1 subunit of the kinase heteromer [55].
Unlike metformin and AICAR which activate AMPK by
inducing the phosphorylation T172 on the alpha subu-
nit, A769662 induced AMPK activation does not require
this post-translational modification [56]. While both
metformin and A769662 led to a full reversal of neuro-
pathic allodynia, A769662 was more potent in vivo and
had a more profound effect on sensory neuron
excitability with a near complete blockade of ramp cur-
rent evoked spiking. Moreover, A769662 (and AICAR)
led to robust ERK inhibition in sensory neurons in cul-
ture whereas metformin had no impact on ERK activity.
While further experimentation will be needed to gain
insight into the exact mechanisms through which differ-
ent modes of AMPK activation achieve differential sig-
naling endpoints, these results point to a potential
pharmacological advantage for positive allosteric modu-
lators of AMPK for the treatment of chronic pain.
Furthermore, the efficacy of A769662 in mouse models
of neuropathic pain suggests that targeting the b1-subu-
nit of AMPK may be a viable drug development target
for the pain pathway.
In conclusion, we have demonstrated a novel pathway
for the potential treatment of neuropathic pain, AMPK
activation. Pharmacological AMPK activation negatively
regulates aberrant translation control after PNI, resolves
neuropathic allodynia and decreases sensory neuron
excitability. Due to the clinical availability and safety of
metformin, these preclinical findings have the potential
to lead to rapid translation into the clinic.
Methods
Surgery and behavioral testing
Male ICR mice (Harlan, 20-25 g) and male Sprague
Dawley rats (Harlan, 250-300 g) were used. All animal
procedures were approved by the Institutional Animal
Care and Use Committee of The University of Arizona
and were in accordance with International Association
for the Study of Pain guidelines. Prior to surgery all ani-
mals were assessed for mechanical withdrawal thresh-
olds [57]. Spared nerve injury (SNI) was performed on
the mice as described previously [58]. Spinal nerve liga-
tion (SNL) was done on rats by tight ligation of the L5
and L6 spinal nerves as described by Kim and Chung
[59]. Sham control animals underwent the same surgery
and handling as the experimental animals but without
the SNL or SNI. All animals were allowed to recover for
14 days and all testing commenced day 14 day post-sur-
gery (except as noted in the text when testing was done
7 weeks post SNI). Following nerve injury, only animals
that developed paw withdrawal thresholds less than 1 g
for SNI and less than 4.7 g for SNL by day 14 post-sur-
gery were used. Animals were placed in acrylic boxes
with wire mesh floors and allowed to habituate for 1 hr.
Pre-drug mechanical thresholds were recorded and the
animals received intraperitoneal injections of vehicle,
metformin (200 mg/kg) [20] or A7969662 (30 mg/kg)
[21]. Calibrated von Frey filaments (Stoelting, Wood
Dale, IL) were used for mechanical stimulation of the
plantar surface of the left hindpaw and withdrawal
thresholds were calculated using the up-down method
[57]. For Western blotting, eIF4F complex formation
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vested 17 days post SNL or SNI unless drug treatments
were initiated on day 14, in which case they were har-
vested on day 21.
Primary neuronal cultures
Mouse trigeminal ganglia (TG) were excised aseptically
and placed in Hank’s Buffered Salt Solution (HBSS, Invi-
trogen) on ice. The ganglia were dissociated enzymati-
cally with collagenase A (1 mg/ml, 25 min, Roche) and
collagenase D (1 mg/ml, Roche) with papain (30 U/ml,
Roche) for 20 min at 37°C. To eliminate debris 70 μm
(BD) cell strainers were used. The dissociated cells were
resuspended in DMEM/F12 (Invitrogen) containing 1×
pen-strep (Invitrogen), 1× GlutaMax, 3 μg/ml 5-FDU
(Sigma), 7 μg/ml uridine (Sigma), 50 ng/ml NGF (Milli-
pore) and 10% fetal bovine serum (Hyclone). The cells
were plated in 6-well plates (BD Falcon) and incubated
at 37°C in a humidified 95% air/5%CO2 incubator. On
day 5 the cells were washed in DMEM/F12 media for 30
mins followed by treatment.
Western blotting
Protein was extracted from the cells and tissue in lysis
buffer (50 mM Tris HCl, 1% Triton X-100, 150 mM
NaCl, and 1 mM EDTA at pH 7.4) containing protease
and phosphatase inhibitor mixtures (Sigma) with an
ultrasonicator on ice, and cleared of cellular debris and
nuclei by centrifugation at 14,000 RCF for 15 min at 4°
C. Fifteen micrograms of protein per well were loaded
and separated by standard 7.5% or 10% SDS-PAGE. Pro-
teins were transferred to Immobilon-P membranes
(Millipore) and then blocked with 5% dry milk for 3 h
at room temperature. The blots were incubated with
primary antibody overnight at 4°C and detected the fol-
lowing day with donkey anti-rabbit antibody conjugated
to horseradish peroxidase (Jackson Immunoresearch).
Signal was detected by ECL on chemiluminescent films.
Each phosphoprotein was normalized to the expression
of the corresponding total protein which in turn were
normalized to GAPDH and bIII tubulin on the same
membrane. Membranes were stripped prior to antibody
incubation for normalization. Densitometric analyses
were performed with Image J software (NIH).
Enzyme Linked Immunosorbent Assay (ELISA)
ELISAs for NGF (Promega) and IL-6 (Thermo) were
performed on the sciatic nerves form rats with SNL
according to the manufacturer’s instruction. The optical
density was read by a plate reader (Multiskan Ascent,
Themo) using a 450 nm filter. Ascent Software (Themo)
was used for the data analysis and cubic spline curve fit
was chosen for that purpose.
5’ mRNA cap complex analysis
After the protein extraction, 50 μgp r o t e i nw a si n c u -
bated with 7- methyl GTP Sepharose 4B beads (GE
Healthcare) in the presence of 100 μMG T Pf o r2ha t
4°C. Unconjugated sepharose 4B beads were used for
the negative controls. The beads were then pelleted and
washed twice with lysis buffer. After a final centrifuga-
tion the pellet was suspended in 1× Laemmli Sample
Buffer containing 5% v/v b-mercaptoethanol and eIF4E,
eIF4G eIF4A and 4EBP bound to the precipitated beads
was analyzed by Western blotting.
Immunohistochemistry
Slide-mounted sections were fixed in ice-cold 3.7% par-
aformaldehyde in 1× PBS for 1 h and then washed 3
times for 5 min in PBS. Slides were transferred to a
solution containing 0.1 M sodium citrate and 0.05%
Tween 20 and then microwaved on high power for 3
min in a 900 W microwave oven for antigen retrieval.
After a 30 min cooling period, slides were again trans-
ferred to 1× PBS, washed 3 times for 5 min, and then
permeabilized in 1× PBS, containing 0.05% Triton X-
100. Slides were then blocked for at least 1 h in 1× PBS,
containing 10% normal goat serum, before the addition
of anti-phospho-mTOR antibody overnight at 4°C. The
antiperipherin and N52 antibodies were applied
together. Immunoreactivity was visualized after subse-
quent incubation with goat anti-rabbit and goat anti-
mouse Alexa-Fluor antibody for 1 h at room tempera-
ture. All immunohistochemistry (IHC) images are repre-
sentative of samples taken from three animals. Confocal
IHC micrographs were acquired on Ziess LSM 510
META NLO upright microscope using a 40×, 1.3
numerical aperture oil immersion objective.
Nascent protein synthesis in sciatic nerves
Ipsilateral and contralateral sciatic nerves from SNL rats
or ipsilateral sciatic nerves from sham rats were excised
at a length of 2 cm. The nerves were then cut to a
length of 1 cm and incubated in DMEM/F12 supple-
mented with 50 μM of Azidohomoalanine (AHA). After
2 hours of incubation at 37°C in a humidified 95% air/
5%CO2 incubator, protein was extracted from the
nerves by ultrasonication in RIPA buffer. AHA incor-
porating proteins were labeled with biotin using Click-
iT Biotin Protein Analysis Detection Kit (Invitrogen).
The samples were analyzed using western blotting with
the biotin labeled proteins detected by avidin-HRP
chemiluminescence.
Patch clamp electrophysiology
Whole cell patch-clamp experiments were performed on
isolated mouse TG using a MultiClamp 700B (Axon
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acquisition software (Axon Instruments). Recordings
w e r es a m p l e da t5k H za n df iltered at 1 kHz (Digidata
1322A, Axon Instruments). Pipettes (OD: 1.5 mm, ID:
0.86 mm, Sutter Instrument) were pulled using a P-97
puller (Sutter Instrument) and heat polished to 2.5-4
MΩ resistance using a microforge (MF-83, Narishige).
Pipette offsets were zeroed automatically before seal for-
mation and liquid junction potentials were not cor-
rected. Pipette capacitance neutralization and bridge
balance were adjusted automatically in current-clamp
mode. All recordings were performed at room tempera-
ture. Data were analyzed using Clampfit 10 (Molecular
Devices) and Origin 8 (OriginLab). Pipette solution con-
t a i n e d( i nm M )1 4 0K C l ,1 1E G T A ,2M g C l 2 ,1 0N a C l ,
10 HEPES, 1CaCl2 pH 7.3 (adjusted with N-methyl glu-
camine), and was 320 mosM. External solution con-
tained (in mM) 135 NaCl, 2 CaCl2, 1 MgCl2, 5 KCl, 10
Glucose and 10 HEPES, pH 7.4 (adjusted with N-methyl
glucamine), and was 320 mosM. The cells were treated
with relevant drug for 1 hour before patch clamp studies
were carried out. Ramp stimulus protocols for Nav1.7
were performed as described previously [44] as these
protocols have been shown to preferentially elicit func-
tion from Nav1.7 channels [60]. The viability of the neu-
rons was verified by eliciting currents in response to a
voltage step protocol before and after each current ramp
protocol was carried out. Al recordings were made on
mouse TG neurons from ~20 gram mice. Capacitance
of all cells analyzed was between 20-30pF.
Drugs and primary antibodies
U-0126 and U0124 were from Tocris; metformin was
from LKT Laboratories; mouse 2.5S NGF was from
Millipore; The following rabbit polyclonal antibodies
were obtained from Cell Signaling: p-ERK (Thr202/
Tyr204, cat# 4377), total ERK, p-eIF4E (Ser209, cat#
9741), total eIF4E, p-mTOR (Ser2448, cat# 2971), total
mTOR, p-4EBP(Thr37/46, cat # 9459), total 4EBP, p-
eIF4G (Ser1108, cat# 2441), total eIF4G, p-AKT
(Ser473, cat# 4058), total AKT, GAPDH and eIF4A.
Mov10 was from Bethyl Labs and rck/p54 was from
MBL international. A769662 was from LC Laboratories.
Statistical Analysis and Data Presentation
Data are shown as means and the standard error of the
mean (± SEM) of eight independent cell culture wells, 6
tissue samples (for in vivo Western blotting, eIF4F com-
plex formation and nascent protein synthesis) or 6 ani-
mals (for behavioral studies). Graph plotting and
statistical analysis used Graphpad Prism Version 5.03
(Graph Pad Software, Inc. San Diego, CA, USA). Statisti-
cal evaluation was performed by one- or two-way analy-
sis of variance (ANOVA), followed by appropriate post-
hoc tests. The a priori level of significance at 95% confi-
dence level was considered at p < 0.05.
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